The etiopathogenesis of schizophrenias

Pharmacopsychiatry

Volumn 37, Issue SUPPL. 2, 2004, Pages

  Kornhuber, Johannes ^a   Wiltfang, J ^a   Bleich, S ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN; CONFERENCE PAPER; DEVELOPMENTAL DISORDER; DISEASE MODEL; GENE LOCUS; HEREDITY; HYPOTHESIS; NERVE CELL DIFFERENTIATION; NEUROTRANSMISSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCHIZOPHRENIA;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, NEUROLOGICAL; NERVE NET; NEURONAL PLASTICITY; NEUROTRANSMITTER AGENTS; PSYCHOLOGICAL THEORY; SCHIZOPHRENIA;

EID: 9744262470     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-832663     Document Type: Conference Paper

References (140)

1. Adams W, Kendell RE, Hare EH, Munk-Jorgensen P. Epidemiological evidence that maternal influenza contributes to the etiology of schizophrenia. Br J Psychiatry 1993; 163: 522-534
2. Akbarian S, Bunney WE, Potkin SG, Wigal SB, Hagman JO, Sandman CA. Altered distribution of nicotamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry 1996; 50: 169-177
3. Andreasen NC, Arndt S, Swayze V, Cizadlo T, Flaum M, O'Leary D, Ehrhardt JC, Yuh WT. Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science 1994; 266: 294-298
4. Andreasen NC, Flashman L, Flaum M, Arndt S, Swayze V, O'Leary DS, Ehrhardt JC, Yuh WTC. Regional brain abnormalities in schizophrenia measured with magnetic resonance imaging. JAMA 1994; 272: 1763-1769
5. Arnold SE, Hyman BT, Van Hoesen GW, Damasio AR. Some cytoarchitectural abnormalities of the entorhinal cortex in schizophrenia. Arch Gen Psychiatry 1991; 48: 625-632
6. Barta PE, Pearlson GD, Powers RE, Richards SS, Tune LE. Auditory hallucinations and smaller superior temporal gyral volume in schizophrenia. Am J Psychiatry 1990; 147: 1457-1462
7. Bassett AS, Honer GH. Evidence for anticipation in schizophrenia. Am J Genet 1994; 54: 314-324
8. Beckmann H, Franzek E, Stöber G. Genetic heterogeneity in catatonic schizophrenia: a family study. Am J Med Genet 1996; 67: 289-300
9. Beckmann H, Jakob H. Pränatale Entwicklungsstörungen von Hirnstrukturen bei schizophrenen Psychosen. Nervenarzt 1994; 65: 454-463
10. Benes FM. Altered glutamatergic and GABAergic mechanisms in the cingulate cortex of the schizophrenic brain. Arch Gen Psychiatry 1995; 52: 1015-1018
11. Benes FM, McSparran J, Bird ED, SanGiovanni JP, Vincent SL. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiatry 1991; 48: 990-1001
12. Benes FM, Sorensen I, Vincent SL, Bird ED, Sathi M. Increased density of glutamate-immunoreactive vertical processes in superficial laminae in cingulate cortex of schizophrenic brain. Cereb Cortex 1992; 2: 503-512
13. Birkmayer W, Danielczyk W, Neumayer E, Riederer P. The balance of biogenic amines as condition for normal behaviour. J Neural Transm 1972; 33: 163-178
14. Bissette G, Nemeroff CB. Neurotensin and the mesocorticolimbic dopamine system. In: Kalivas PW, Nemeroff CB, editors. The mesocorticolimbic system Ann NY Acad Sci; Vol 537 New York: 1988: 397-404
15. Bleuler E. Dementia praecox oder Gruppe der Schizophrenien. In: Aschaffenburg G, editor. Handbuch der Psychiatrie. Spez. Teil, 4. Abtlg Leipzig-Wien: Deuticke, 1911
16. Bogerts B, Ashtari M, Degreef G, Alvir JM, Bilder RM, Lieberman JA. Reduced temporal limbic structure volumes on magnetic resonance images in first episode schizophrenia. Psychiatry Res Neuroimaging 1990; 35: 1-13
17. Bogerts B, Meertz E, Schönfeldt-Bausch R. Basal ganglia and limbic system pathology in schizophrenia: a morphometric study of brain volume and shrinkage. Arch Gen Psychiatry 1985; 42: 784-791
18. Bracha HS, Torrey EF, Bigelow LB, Lohr JB, Linington BB. Subtle signs of prenatal maldevelopment of the hand ectoderm in schizophrenia: a preliminary monozygotic twin study. Biol Psychiatry 1991; 30: 719-725
19. Bradbury TN, Miller GA. Season of birth in schizophrenia: a review of evidence, methodology, and etiology. Psychol Bull 1985; 98: 569-594
20. Bruton CJ, Crow TJ, Frith CD, Johnstone EC, Owens DGC, Roberts GW. Schizophrenia and the brain: a prospective clinico-neuropathological study. Psychol Med 1990; 20: 285-304
21. Cantor-Graae E, McNeil TF, Torrey EF, Quinn P, Bowler A, Sjöström K, Rawlings R. Link between pregnancy complications and minor physical anomalies in monozygotic twins discordant for schizophrenia. Am J Psychiatry 1994; 151: 1188-1193
22. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988; 1: 179-186
23. Carlsson A, Lindquist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963; 20: 140-144
24. Carlsson A, Waters N, Hansson LO. Neurotransmitter aberrations in schizophrenia: new findings, In: Fog R, Gerlach J, Hemmingsen R, editors. Schizophrenia. An integrated view Copenhagen: Munksgaard, 1995: 332-340
25. Carlsson M, Carlsson A. Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice. J Neural Transm 1989; 77: 65-71
26. Carlsson M, Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci 1990; 13: 272-276
27. Carlsson M, Svensson A, Carlsson A. Synergistic interactions between muscarinic antagonists, adrenergic agonists and NMDA antagonists with respect to locomotor stimulatory effects in monoamine-depleted mice. Naunyn Schmiedebergs Arch Pharmacol 1991; 343: 568-573
28. 2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse-implications for psychosis. J Neural Transm Gen Sect 1995; 100: 225-237
29. Chen HS, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, Lipton SA. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 1992; 12: 4427-4436
30. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192: 481-483
31. Crow TJ, Done DJ. Prenatal exposure to influenza does not cause schizophrenia. Br J Psychiatry 1992; 161: 390-393
32. Deakin JFW, Slater P, Simpson MD, Gilchrist AC, Skan WJ, Royston MC, Reynolds GP, Cross AJ. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem 1989; 52: 1781-1786
33. Deckert J, Gleiter CH. Adenosinergic psychopharmaceuticals: just an extra cup of coffee? J Psychopharmacol 1990; 4: 183-187
34. Degreef G, Ashtari M, Bogerts B, Bilder RM, Jody DN, Alvir JM. Lieberman JA. Volumes of ventricular system subdivisions measured from magnetic resonance images in first-episode schizophrenic patients. Arch Gen Psychiatry 1992; 49: 531-537
35. DeLisi LE, Hoff AL, Schwartz JE, Shields GW, Halthore SN, Gupta SM, Henn FA, Anand AK. Brain morphology in first-episode schizophrenic-like psychotic patients: a quantitative magnetic resonance imaging study [erratum: Biol Psychiatry 1991, 29: 519]. Biol Psychiatry 1991; 29: 159-175
36. DeLisi LE, Hoff AL, Schwartz JE, Shields GW, Halthore SN, Gupta SM, Henn FA, Anand AK. Brain morphology in first-episode schizophrenic-like psychotic patients: a quantitative magnetic resonance imaging study [erratum: Biol Psychiatry 1991, 29: 519]. Biol Psychiatry 1991; 29: 159-175
37. Done DJ, Crow TJ, Johnstone EC, Sacker A. Childhood antecendents of schizophrenia and affective illness: social adjustment at ages 7 and 11. Br Med J 1994; 309: 699-703
38. Farmer AE, McGuffin P, Gottesman II. Twin concordance and DSM III schizophrenia: scrutinizing the validity of the definition. Arch Gen Psychiatry 1987; 44: 634-640
39. Fish B, Marcus J, Hans SL, Auerbach JG, Perdue S. Infants at risk for schizophrenia: sequelae of a genetic neurointegrative defect. A review and replication analysis of pandysmaturation in the Jerusalem Infant Development Study. Arch Gen Psychiatry 1992; 49: 221-235
40. Franzek E, Beckmann H. Season-of-birth effect reveals the existence of etiologically different groups of schizophrenia. Biol Psychiatry 1992; 32: 375-378
41. Franzek E, Beckmann H. Die genetische Heterogenität der Schizophrenie. Ergebnisse einer systematischen Zwillingsstudie. Nervenarzt 1996; 67: 583-594
42. Fritze J. Einführung in die biologische Psychiatrie. Stuttgart New York: Gustav Fischer, 1989
43. Garbutt JC, van Kammen DP. The interaction between GABA and dopamine: implications for schizophrenia. Schizophr Bull 1983; 9: 336-353
44. Gattaz WF, Gasser T, Beckmann H. Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls. Biol Psychiatry 1985; 20: 360-366
45. Geddes JR, Lawrie SM. Obstetric complications and schizophrenia: a meta-analysis. Br J Psychiatry 1995; 167: 786-793
46. Goldman-Rakic PS. Glutamate and dopamine interaction in the primate cortex: implications for frontal lobe function and schizophrenia. Neuropsychopharmacology 1994; 10: 229
47. Goldman-Rakic PS. Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci 1994; 6: 348-357
48. Gottesman II. Schizophrenia genesis. New York: W.H. Freeman, 1991
49. Gottesman II, Bertelsen A. Confirming unexpressed genotypes for schizophrenia: risks in the offspring of Fischer's Danish identical and fraternal discordant twins. Arch Gen Psychiatry 1989; 46: 867-872
50. Gottesman II, Shields J. Schizophrenia, the epigenetic puzzle. Cambridge: Cambridge University Press, 1982
51. Green MF, Satz P, Gaier DJ, Ganzell S, Kharabi F. Minor physical abnormalies in schizophrenia. Schizophr Bull 1989; 15: 91-99
52. Griffon N, Sokoloff P, Diaz J, Lévesque D, Sautel F, Schwartz JC, Simon P, Costentin J, Garrido F, Mann A, Wermuth C. The dopamine D3 receptor and schizophrenia: pharmacological, anatomical and genetic approaches. Eur Neuropsychopharmacol Suppl 1995; 5: 3-9
53. Gross G, Huber G. Sensorische Störungen bei Schizophrenien. Arch Psychiatr Nervenkr 1972; 216: 119-130
54. Hansson LO, Waters N, Winblad B, Gottfries C-G, Carlsson A. Evidence for biochemical heterogeneity in schizophrenia: a multivariate study of monoaminergic indices in human post-mortal brain tissue. J Neural Transm Gen Sect 1994; 98: 217-235
55. Harrison PJ, Owen MJ. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 2003; 361: 417-419
56. Hodge SE. What association analysis can and cannot tell us about the genetics of complex disease. Am J Med Genet 1994; 54: 318-323
57. Hodge SE, Wickramaratne P. Statistical pitfalls in detecting age-of-onset anticipation: the role of correlation in studying anticipation and detecting ascertainment. Psychiatr Genet 1995; 5: 43-47
58. Hoff AL, Riordan H, O'Donnell DW, Morris L, DeLisi LE. Neuropsychological functioning of first-episode schizophreniform patients. Am J Psychiatry 1992; 149: 898-903
59. Huber G. Die coenästhetische Schizophrenie. Fortschr Neurol Psychiat 1957; 25: 491-520
60. Huber G. Pneumencephalographische und psychopathologische Bilder bei endogenen Psychosen. Berlin Göttingen Heidelberg: Springer, 1957
61. Hudson CJ, Young LT, Li PP, Warsh JJ. CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia. Synapse 1993; 13: 278-293
62. Jacobi W, Winkler H. Encephalographische Studien an chronischen Schizophrenen. Arch Psychiatr Nervenkr 1927; 81: 299-332
63. Jakob H, Beckmann H. Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J Neural Transm 1986; 65: 303-326
64. Jaskiw GE, Juliano DM, Goldberg TE, Hertzman M, Urow-Hamell E, Weinberger DR. Cerebral ventricular enlargement in schizophreniform disorder does not progress - a seven year follow-up study. Schizophr Res 1994; 14: 23-28
65. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-1308
66. Karson CN, Casanova MF, Kleinman JE, Griffin WST. Choline acetyltransferase in schizophrenia. Am J Psychiatry 1993; 150: 454-459
67. Kendler KS, Diehl SR. The genetics of schizophrenia: a current, genetic-epidemiologic perspective. Schizophr Bull 1993; 19: 261-285
68. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmüller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 1980; 20: 379-382
69. Kornhuber HH, Kornhuber J, Kim JS, Kornhuber ME. Zur biochemischen Theorie der Schizophrenie. Nervenarzt 1984; 55: 602-606
70. Kornhuber J, Beckmann H, Riederer P. Die glutamatergen und sigmaergen Systeme bei den Schizophrenien. In: Beckmann H, Osterheider M, editors. Neurotransmitter und psychische Erkrankungen Berlin: Springer Verlag, 1991: 147-157
71. Kornhuber J, Bormann J, Hübers M, Rusche K, Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol Mol Pharmacol Sect 1991; 206: 297-300
72. 3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 1989; 166: 589-590
73. Kornhuber J, Herr B, Thome J, Riederer P. The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue. J Neural Transm Suppl 1995; 46: 131-137
74. 3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm 1989; 77: 231-236
75. Kornhuber J, Parsons CG, Hartmann S, Retz W, Kamolz S, Thome J, Riederer P. Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J Neural Transm Gen Sect 1995; 102: 237-246
76. 3H-Spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms. J Neural Transm 1989; 75: 1-10
77. Kornhuber J, Weller M. Aktueller Stand der biochemischen Hypothesen zur Pathogenese der Schizophrenien. Nervenarzt 1994; 65: 741-754
78. Kornhuber J, Weller M. Predicting psychotomimetic properties of PCP-like NMDA receptor antagonists. In: Fog R, Gerlach J, Hemmingsen R, Krogsgaard-Larsen P, Thaysen JH, editors. Schizophrenia - An integrated view. Alfred Benzon Symposium 38. Copenhagen: Munksgaard, 1995: 314-325
79. Kornhuber J, Weller M. Neue therapeutische Möglichkeiten mit niederaffinen NMDA-Rezeptorantagonisten. Nervenarzt 1996; 67: 77-82
80. Kornhuber J, Weller M. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 1997; 41: 135-144
81. Kornhuber ME, Kornhuber J, Zettlmeissl H, Kornhuber HH. Phencyclidin und das glutamaterge System. In: Keupp W, editor. Biologische Psychiatrie, Forschungsergebnisse, Berlin New York: Springer, 1986: 176-180
82. Kraepelin E. Psychiatrie. Ein Lehrbuch für Studierende und Ärzte, Bd. 1-4, 1909-1915; 8th ed Leipzig: Barth, 1909
83. Kruglyak L, Lander ES. High-resolution genetic mapping of complex traits. Am J Hum Genet 1995; 56: 1212-1223
84. Lesch KP, Stöber G, Balling U, Franzek E, Li SH, Ross CA, Newman M, Beckmann H, Riederer P. Triplet repeats in clinical subtypes of schizophrenia: variation at the DRPLA (B37 CAG repeat) locus is not associated with periodic catatonia. J Neural Transm Gen Sect 1994; 98: 153-157
85. Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I, Williams NM, Schwab SG, Pulver AE, Faraone SV, Brzustowicz LM, Kaufmann CA, Garver DL, Gurling HM, Lindholm E, Coon H, Moises HW, Byerley W, Shaw SH, Mesen A, Sherrington R, O'Neill FA, Walsh D, Kendler KS, Ekelund J, Paunio T, Lonnqvist J, Peltonen L, O'Donovan MC, Owen MJ, Wildenauer DB, Maier W, Nestadt G, Blouin JL, Antonarakis SE, Mowry BJ, Silverman JM, Crowe RR, Cloninger CR, Tsuang MT, Malaspina D, Harkavy-Friedman JM, Svrakic DM, Bassett AS, Holcomb J, Kalsi G, McQuillin A, Brynjolfson J, Sigmundsson T, Petursson H, Jazin E, Zoega T, Helgason T. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet 2003; 73: 34-48
86. Lewis SW, Murray RM. Obstetric complications, neurodevelopmental deviance, and risk of schizophrenia. J Psychiatr Res 1987; 21: 413-421
87. Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Frackowiak RS. Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 1992; 160: 179-186
88. Lieberman JA, Koreen AR. Neurochemistry and neuroendocrinology of schizophrenia: a selective review. Schizophr Bull 1993; 19: 371-429
89. Lohr JB, Flynn K. Minor physical anomalies in schizophrenia and mood disorders. Schizophr Bull 1993; 19: 551-556
90. Maier W, Zobel A, Rietschel M. Genetics of schizophrenia and affective disorders. Pharmacopsychiatry 2003; 36(Suppl 3): S195-202
91. Malmberg A, Jackson DM, Eriksson A, Mohell N. Unique binding characterisitcs of antipsychotic agents interacting with human dopamine D2A, D2B and D3 receptors. Mol Pharmacol 1993; 43: 749-754
92. McGuffin P, Owen MJ, Farmer AE. Genetic basis of schizophrenia. Lancet 1995; 346: 678-682
93. McGuffin P, Sargeant M, Hett G, Tidmarsh S, Whatley S, Marchbanks RM. Exclusion of a schizophrenia susceptibility gene from the chromosome 5q11-q13 region: new data and a re-analysis of previous reports. Am J Hum Genet 1996; 47: 524-535
94. McNeil TF. Obstetric complications in schizophrenic parents. Schizophr Res 1991; 5: 89-101
95. Meadows De, Meadows Do, Zahn E, Milling P. Die Grenzen des Wachstums. Bericht des Club of Rome zur Lage der Menschheit. Reinbek: Rowohlt, 1973
96. Mednick SA, Machon RA, Huttunen MO, Bonett D. Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch Gen Psychiatry 1988; 45: 189-192
97. i values. J Pharmacol Exp Ther 1989; 251: 238-246
98. Moises HW, Yang L, Kristbjarnarson H, Wiese C, Byerley W, Macciardi F, Arolt V, Blackwood D, Liu X, Sjogren B, et al. An international two-stage genome-wide search for schizophrenia susceptibility genes. Nat Genet 1995; 11: 321-324
99. Murray RM, Lewis SW. Is schizophrenia a neurodevelopmental disorder? Br Med J 1987; 296: 681-682
100. Nair NPV, Lal S, Bloom DM. Cholecystokinin and schizophrenia. In: van Ree JM, Matthysse S, editors. Progress in Brain Research; Vol 65 Amsterdam: Elsevier, 1994: 237-258
101. O'Callaghan E, Gibson T, Colohan HA, Walshe D, Buckley P, Larkin C, Waddington JL. Season of birth in schizophrenia. Evidence for confinement of an excess of winter births to patients without a family history of mental disorder. Br J Psychiatry 1991; 158: 764-769
102. O'Callaghan E, Larkin C, Kinsella A, Waddington JL. Familial, obstetric, and other clinical correlates of minor physical anomalies in schizophrenia. Am J Psychiatry 1991; 148: 479-483
103. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989; 244: 1360-1362
104. Pakkenberg B. Post-mortem study of chronic schizophrenic brains. Br J Psychiatry 1987; 151: 744-752
105. Parsons CG, Gruner R, Rozental J, Millar J, Lodge D. Patch clamp studies on the kinetic and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 1993; 32: 1337-1350
106. Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, Krzascik P, Hartmann S, Danysz W. Comparison of the potency, kinetics and voltage-dependency of open channel blockade for a series of uncompetitive NMDA antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 1995; 34: 1239-1258
107. Porenta G, Riederer P. Some aspects of modeling neuronal interactions in the basal ganglia. In: Trappl R, editor. Cybernetics and systems '86 D. Reidel Publishing Company, 1986: 351-358
108. Pulver AE, Lasseter VK, Kasch L, Wolyniec P, Nestadt G, Blovin JL, Kimberland M, Babb R, Vourlis S, Chen H, et al. Schizophrenia: a genome scan targets chromosomes 3p and 8p as potential sites of susceptibility. Am J Med Genet 1995; 60: 252-260
109. Reading PJ. Frontal lobe dysfunction in schizophrenia and Parkinson's disease - a meeting point of neurology, psychology and psychiatry: a discussion paper. J R Soc Med 1991; 84: 349-353
110. Reveley AM, Reveley MA, Clifford CA, Murray RM. Cerebral ventricular size in twins discordant for schizophrenia. Lancet 1982; ii: 540-541
111. Reynolds GP. Beyond the dopamine hypothesis. The neurochemical pathology of schizophrenia. Br J Psychiatry 1989; 155: 305-316
112. Reynolds GP. Dopamine D4 receptors in schizophrenia [letter]? J Neurochem 1996; 66: 881-883
113. Reynolds GP, Mason SL. Are striatal dopamine D4 receptors increased in schizophrenia? J Neurochem 1994; 63: 1576-1577
114. Ross CA, Pearlson GD. Schizophrenia, the heteromodal association neocortex and development: potential for a neurogenetic approach. Trends Neurosci 1996; 19: 171-176
115. Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P, Gur RC. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 1994; 51: 124-131
116. Scheibel AB, Kovelman JA. Disorientation of the hippocampal pyramidal cell and its processes in the schizophrenic patient. Biol Psychiatry 1981; 16: 101-102
117. Schwab SG, Albus M, Hallmayer J, Honig S, Borrmann M, Lichtermann D, Ebstein RP, Ackenheil M, Lerer B, Risch N, et al. Evaluation of a susceptibility gene for schizophrenia on chromosome 6p by multipoint affected sib-pair linkage analysis. Nat Genet 1995; 11: 325-327
118. Schwab SG, Lerer B, Albus M, Maier W, Hallmayer J, Fimmers R, Lichtermann D, Minges J, Bondy B, Ackenheil M, Altmark D, Hasib D, Gur E, Ebstein RP, Wildenauer DB. Potential linkage for schizophrenia an chromosome 22q12-q13: a replication study. Am J Med Genet 1995; 60: 436-443
119. Schwartz JC, Diaz J, Lévesque D, Pilon C, Dimitriadou V, Griffon N, Lammers C, Martres MP, Sokoloff P. The D2-like subfamily of dopamine receptors. In: Fog R, Gerlach J, Hemmingsen R, editors. Schizophrenia. An integrated view Copenhagen: Munksgaard, 1995: 251-262
120. Seeman P, Guan H-G, Van Tol HHM. Dopamine D4 receptors elevated in schizophrenia. Nature 1993; 365: 441-445
121. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717-719
122. Shenton ME, Kikinis R, Jolesz FA, Pollak SD, LeMay M, Wible CG, Hokama H, Martin J, Metcalf D, Coleman M, et al. Abnormalities of the left temporal lobe and thought disorder in schizophrenia. A quantitative magnetic resonance imaging study. N Engl J Med 1992; 327: 604-612
123. Sherrington R, Brynjolfsson B, Petursson H, Potter M, Dudleston K, Barraclough B, Wasmuth J, Dobbs M, Gurling H. Localization of a susceptibility locus for schizophrenia on chromosome 5. Nature 1988; 336: 164-167
124. Stöber G, Franzek E, Beckmann H. Obstetric complications in distinct schizophrenic subgroups. Eur Psychiatry 1993; 8: 293-299
125. Stöber G, Franzek E, Beckmann H. Schwangerschaftsinfektionen bei Müttern von chronisch Schizophrenen. Die Bedeutung einer differenzierten Nosologie. Nervenarzt 1994; 65: 175-182
126. Stöber G, Franzek E, Lesch KP, Beckmann H. Periodic catatonia: a schizophrenic subtype with major gene effect and anticipation. Eur Arch Psychiatry Clin Neurosci 1995; 245: 135-141
127. Straub RE, MacLean CJ, O'Neill FA, Burke J, Murphy B, Duke F, Shinkwin R, Webb BT, Zhang J, Walsh D, et al. A potential vulnerability locus for schizophrenia on chromosome 6p24-22: evidence for genetic heterogeneity. Nat Genet 1995; 11: 287-293
128. Suddath RL, Christison GW, Torrey EF, Weinberger DR. Cerebral anatomical abnormalities in monozygotic twins discordant for schizophrenia. N Engl J Med 1990; 322: 789-794
129. Svensson A, Carlsson ML, Carlsson A. Interaction between glutamatergic and dopaminergic tone in the nulcleus accumbens of mice: evidence for a dual glutamatergic function with respect to psychomotor control. J Neural Transm 1992; 88: 235-240
130. Tandon R, Greden JF. Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Arch Gen Psychiatry 1989; 46: 745-753
131. Thomson G. Identifying complex disease genes: progress and paradigms. Nat Genet 1994; 8: 108-110
132. Vita A, Sacchetti E, Valvassori G, Cazzullo CL. Brain morphology in schizophrenia: a 2- to 5-year follow-up study. Acta Psychiatr Scand 1988; 78: 618-621
133. Waddington JL. Schizophrenia: developmental neuroscience and pathobiology. Lancet 1993; 341: 531-536
134. Walker JM, Bowen WD, Walker FO, Matsumoto RR, De Costa B, Rice KC. Sigma receptors: biology and function. Pharmacol Rev 1990; 42: 355-402
135. Warren ST. The expanding world of trinucleotide repeats. Science 1996; 271: 1374-1375
136. Weinberger DR. Implications of normal brain development for the. pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44: 660-669
137. Weinberger DR. Schizophrenia and the frontal lobe. Trends Neurosci 1988; 11: 367-370
138. Wiegant VM, Ronken E, Kovács G, de Wied D. Endorphins and schizophrenia. Prog Brain Res 1992; 93: 433-453
139. Winn P. Schizophrenia search moves to the prefrontal cortex. Trends Neurosci 1994; 17: 265-268
140. Zipursky RB, Marsh L, Lim KO, DeMent S, Shear PK, Sullivan EV, Murphy GM, Csernansky JG, Pfefferbaum A. Volumetric MRI assessment of temporal lobe structures in schizophrenia. Biol Psychiatry 1994; 35: 501-516